

PRESS RELEASE**Metropolis Healthcare to Acquire Dehradun's Leading Diagnostic Chain, Dr. Ahujas' Pathology & Imaging Centre, Strengthening Its Position in North India.**

India, Mumbai, 7th April 2025: Ameera Shah-led Metropolis Healthcare Limited (NSE: METROPOLIS | BSE: 542650), India's second-largest and most respected pathology laboratory chain, today announced that its wholly owned subsidiary, Metropolis Histoexpert Digital Services Private Limited, has entered into a business transfer agreement to acquire Dehradun's leading diagnostic chain - **Dr. Ahujas' Pathology and Imaging Centre (DAPIC)**.

Founded in 1990 by Dr. Alok Ahuja and Dr. Alka Ahuja, DAPIC has established itself as a trusted name in Uttarakhand's diagnostic sector, known for its high standards of quality and accuracy. The organization operates two laboratories accredited by NABL and NABH, 11 patient service centres, and nine hospital-based centres. It offers a comprehensive range of pathology and soft radiology services, including ultrasound, ECG, and X-ray. In FY 2024-25, DAPIC recorded an estimated annual revenue of INR 11.5 crore (*unaudited**), with pathology services contributing 73% and radiology services 27%. With 80 percent of its revenue coming from walk-in patients, the chain has built a strong B2C presence, making it a valuable addition to Metropolis' growing network in North India.

Under the agreement, Metropolis' wholly owned subsidiary Metropolis Histoexpert Digital Services Private Limited, will acquire 100% ownership of DAPIC in an all-cash deal valued at INR 35.01 crores. To ensure a seamless transition, Dr. Alok Ahuja and Dr. Alka Ahuja will continue their association with the business post-acquisition.

Commenting on the acquisition, Ms. Ameera Shah, Promoter and Executive Chairperson, Metropolis Healthcare Limited, said: "Dr. Ahujas' Pathology & Imaging Centre has established a strong reputation for high-quality B2C services, scientific excellence, and patient trust, making it an ideal addition to Metropolis' growth strategy. Together with the acquisition of Core Diagnostics, a leader in oncology testing, Scientific Pathology, the dominant chain in Agra, and now DAPIC, the leading diagnostic chain in Dehradun, we are further strengthening our 'String of Pearls' strategy—aimed at building a robust and regionally diverse diagnostic network across North India. These strategic moves have expanded the North India contribution to our overall revenues from 8% to an estimated 14–15%. Building on this momentum, we aim to accelerate our expansion across Uttar Pradesh and Uttarakhand—two high-growth markets with significant potential. We are delighted to welcome Dr. Alok Ahuja and Dr. Alka Ahuja into the Metropolis family as we integrate DAPIC to further enhance patient care."

Mr. Surendran Chemmenkotil, Chief Executive Officer, Metropolis Healthcare Limited, said: "Uttarakhand is one of the fastest-growing diagnostic markets in North India, valued at approximately INR 500 crore. This acquisition strengthens our presence, expanding access to high-quality diagnostics while deepening engagement with doctors and patients. With the combined strength of DAPIC's established network of labs and centres and Metropolis' existing laboratory and six centres in Dehradun, we are now the second-largest diagnostic chain in Uttarakhand. This integration will enhance both B2B and B2C reach with a



comprehensive test portfolio, including specialized diagnostics. Furthermore, we will expand accessibility through a structured franchise model, reinforcing our commitment to scientific excellence and superior healthcare delivery."

Dr. Alok Ahuja, Founder of Dr. Ahujas' Pathology & Imaging Centre, said: "Metropolis Healthcare is one of the most respected diagnostic chains in India, synonymous with quality, scientific expertise, and patient trust. This partnership marks the perfect alignment for DAPIC's next phase of growth. Our team has earned the trust of both the medical fraternity and the public in Uttarakhand, and we believe this collaboration will further elevate service standards and accessibility. With Metropolis' advanced testing capabilities and strong brand recognition, we are confident of driving meaningful growth and innovation in the region—while preserving the legacy of excellence that DAPIC is known for."

EY was the exclusive financial adviser to DAPIC and BDO India LLP acted as the financial advisor to Metropolis Healthcare Limited.

About Metropolis Healthcare Limited: Established in 1981, Metropolis Healthcare Limited is India's second-largest diagnostic chain, led by visionary leader Ms. Ameera Shah, Promoter and Executive Chairperson. With over four decades of excellence, Metropolis has been a pioneer in delivering best-in-class diagnostic services to patients, healthcare providers, and corporates across India and Africa. The company's extensive footprint spans 22 states, 3 Union Territories, and over 700 towns in India, supported by a robust network of more than 200 laboratories, 4,300 service centres, and over 10,000 touchpoints. Each year, Metropolis serves millions of individuals by providing actionable health insights that empower better clinical outcomes.

Metropolis offers a comprehensive range of more than 4,000 tests and profiles, including advanced tests for diagnosing cancer, neurological disorders, infectious diseases, and various genetic abnormalities. The company's commitment to quality and accuracy is reinforced by its consistent CAP proficiency score of over 98% for the past decade, placing it among the top 1% of laboratories worldwide for quality assurance. The Metropolis philosophy is built on the pillars of technological superiority, a warm, patient-centric approach, and reliable diagnostic reports. For more information, please visit www.metropolisindia.com or click on [Twitter](#), [Facebook](#), or [LinkedIn](#)

For further details please contact:

Metropolis Healthcare Ltd	Avian WE
Head - Corporate Communications: Jeyasingh Balakrishnan- +91 9833836185 jeyasingh.b@metropolisindia.com	Aniket Singh Saran: +91 9560476715 aniket@avianwe.com